D.E. Shaw & Co
LENZ

D.E. Shaw & Co’s LENZ Therapeutics LENZ Stock Holding History

D.E. Shaw & Co’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,447
Closed -$215K – 4827
2024
Q4 		$215K Buy
+7,447
New +$227K ﹤0.01% 4053
2023
Q4 		– Sell
-6,775
Closed -$118K – 4674
2023
Q3 		$118K Buy
6,775
+1,077
+19% +$18.7K ﹤0.01% 3840
2023
Q2 		$104K Buy
5,698
+1,357
+31% +$27.1K ﹤0.01% 3828
2023
Q1 		$74.4K Buy
4,341
+15
+0.3% +$243 ﹤0.01% 4004
2022
Q4 		$101K Hold
4,326
– – ﹤0.01% 4363
2022
Q3 		$96K Sell
4,326
-2,395
-36% -$57.1K ﹤0.01% 4602
2022
Q2 		$129K Buy
+6,721
New +$150K ﹤0.01% 4676
2021
Q4 		– Sell
-7,639
Closed -$876K – 5764
2021
Q3 		$876K Buy
+7,639
New +$1.13M ﹤0.01% 3712

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

D.E. Shaw & Co's LENZ Position: Q1 2025 in Review

D.E. Shaw & Co sold out of LENZ Therapeutics (LENZ) in Q1 2025, closing a stake of 7,447 shares — an estimated $215K sold.

D.E. Shaw & Co first reported a position in LENZ in Q3 2021 and held it in 8 quarters. The position peaked at $876K in Q3 2021. 105 funds tracked by Wall St. Rank hold LENZ as of Q1 2025.

  • D.E. Shaw & Co reported no remaining LENZ Therapeutics position as of Q1 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 7,447 LENZ Therapeutics shares in Q1 2025, an estimated $215K.
  • D.E. Shaw & Co first reported a position in LENZ Therapeutics in Q3 2021 and held it in 8 quarters.
  • D.E. Shaw & Co's LENZ Therapeutics position peaked at $876K in Q3 2021.
  • 105 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2025.

Based on D.E. Shaw & Co's 13F filing for Q1 2025, filed 15 May 2025.